Affiliation:
1. The Maudsley Hospital London
2. Department of Psychological Medicine Institute of Psychiatry Denmark Hill London
Abstract
SUMMARY We review advances in the treatment of schizophrenia. We begin with an overview of antipsychotic drug development, focusing on the in vitro and in vivo binding profiles of clozapine and a new generation of D2:5HT antagonists. We then consider the main barriers to effective treatment: non‐compliance (and side‐effects) of medication, recurrent relapse, ‘treatment resistance’, negative symptoms and neurocognitive deficits. Within this framework, we review the mechanisms of action and clinical uses of the ‘atypical’ antipsychotic drugs. We also show how a variety of psychosocial interventions, particularly those that incorporate cognitive techniques, can be used in combination with pharmacotherapy to overcome the same clinical hurdles.
Reference190 articles.
1. Utilisation en therpeutique psychiatrique d'une phenothiazine d'action centrale elective;Delay J;Ann Med Psychol,1952
2. Brain receptors for antipsychotic drugs and dopamine: direct binding assays.
3. Antipsychotic drug doses and neuroleptic/dopamine receptors
4. Dopamine and the pharmacology of schizophrenia: The state of the evidence
5. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values;Meltzer HY;J Pharmacol Exp Ther,1989
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献